← 產業報告目錄

Hematology Analyzers and Reagents Market by Product [Instrument (PoC, 5 part, 6 part), Reagents, slide stainers] & Service, Price (High, Mid, Low), Application (Infectious Diseases, Blood Cancer), End User (Hospital, CTL, Govt Lab) — Global Forecast to 2031

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2026-05-12頁數 292報告編號 MD2479

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global hematology analyzers and reagents market is projected to reach USD 10.33 billion by 2031 from USD 7.57 billion in 2026, growing at a CAGR of 6.4% during the forecast period. Advancements in hematology analyzers and reagents are expected to be a primary driver of market growth in the coming years. However, the high costs of hematology analyzers and reagents, the shortage of skilled experts in emerging nations, and the slow adoption of advanced hematology devices in these regions could hinder growth in the hematology analyzers and reagents market. “The hematology products and services segment held the largest share of the market in 2025.” The global market for hematology analyzers and reagents, by product and service, is segmented into hematology products & services, hemostasis products & services, and immunohematology products & services. Hematology products & services hold a dominant position in the global market for hematology analyzers and reagents. This segment is further divided into: instruments, reagents, consumables, and services. Factors driving growth include higher test volumes, rising prevalence of hematological conditions, and technological advancements such as the introduction of five- and six-part differential analyzers, flow cytometry, and artificial intelligence. “The low-range hematology analyzers segment held the largest share of the market in 2025.” Based on price range, the hematology analyzers and reagents market is segmented into high-range hematology analyzers, mid-range hematology analyzers, and low-range hematology analyzers. It is anticipated that the market will be led by the low-range hematology analyzers segment throughout the forecast period. The anticipation of the dominance of the low-range hematology analyzer segment stems from its cost-effectiveness and ability to perform well in limited-resource environments, such as small labs and diagnostic centers. They come with a 3-part differential, small in size, smaller sample volumes, and are easy to operate. A breakdown of the primary participants referred to for this report is provided below: • By Company Type: Tier 1–40%, Tier 2–30%, and Tier 3– 30% • By Designation: C-level–27%, Director-level–18%, and Others–55% • By Region: North America–40%, Europe–32%, Asia Pacific–20%, Latin America–5%, and the Middle East & Africa–3% The prominent players in the hematology analyzers and reagents market are F. Hoffmann-La Roche Ltd (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Diatron (Hungary), Drew Scientific (US), Siemens Healthineers (Germany), Sysmex Corporation (Japan), Bio-Rad Laboratories, Inc. (US), Horiba Ltd. (Japan), Nihon Kohden Corporation (Japan), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), BioSystems (Spain), and QuidelOrtho Corporation (US), among others. Research Coverage This report studies the hematology analyzers and reagents market based on product and service, price range, application, end user, and region. It also covers the factors driving market growth, analyzes the opportunities and challenges in the market, and provides details on the competitive landscape for market leaders. Furthermore, the report analyzes micro markets by their individual growth trends and forecasts revenue for the market segments across five main regions (and the respective countries within these regions). Reasons to Buy the Report The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the following strategies to strengthen their market presence. This report provides insights into the following pointers: • Analysis of key drivers (rapid integration of AI technology for increased accuracy of diagnosis and optimized hematology analysis workflows, advanced parameters and multi-functionality behind increasing use of hematology analyzers, growing requirements for affordable and efficient tests with first-pass yield and less reagents usage), restraints (expensive advanced hematology analyzer instruments hampering their implementation in healthcare institutions and limited accuracy of digital morphology analyzers in identifying abnormal cells), opportunities (expanding use of AI-based telehematology solutions and precision diagnostics offering advanced cell analysis and rare cell detection capabilities), and challenges (Increased complexity of data management and analysis due to the advent of next-generation hematology analyzers and laboratory shortages affecting workflow efficiency of hematology) influencing the growth of the contrast media market • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in hematology analyzers and reagents market • Market Development: Comprehensive information about lucrative markets–the report analyses the hematology analyzers and reagents market across varied regions • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the hematology analyzers and reagents market Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players
目錄 Table of Contents
1 INTRODUCTION 26 1.1 STUDY OBJECTIVES 26 1.2 MARKET DEFINITION 26 1.3 STUDY SCOPE 27 1.3.1 MARKETS COVERED AND REGIONAL SCOPE 27 1.3.2 INCLUSIONS AND EXCLUSIONS 28 1.3.3 YEARS CONSIDERED 30 1.4 CURRENCY CONSIDERED 30 1.5 STAKEHOLDERS 30 1.6 SUMMARY OF CHANGES 31 2 EXECUTIVE SUMMARY 33 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 33 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 35 2.3 DISRUPTIVE TRENDS IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 36 2.4 HIGH-GROWTH SEGMENTS 37 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 38 3 PREMIUM INSIGHTS 39 3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 39 3.2 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION 40 3.3 HEMATOLOGY ANALYZERS AND REAGENTS MARKET IN ASIA PACIFIC, BY END USER AND COUNTRY 41 3.4 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY GEOGRAPHY 42 4 MARKET OVERVIEW 43 4.1 INTRODUCTION 43 4.2 MARKET DYNAMICS 43 4.2.1 DRIVERS 44 4.2.1.1 Rapid integration of AI to enhance diagnostic accuracy and optimize hematology workflows 44 4.2.1.2 Growing preference for high-parameter and multi-functional testing 45 4.2.1.3 Mounting demand for cost-efficient hematology analyzers 46 4.2.2 RESTRAINTS 46 4.2.2.1 High cost of advanced hematology analyzers 46 4.2.2.2 Limited accuracy of digital morphology analyzers in detecting rare and complex cell abnormalities 47   4.2.3 OPPORTUNITIES 47 4.2.3.1 Expansion of AI-enabled tele-hematology and remote diagnostics 47 4.2.3.2 Adoption of precision diagnostics enabling advanced cell profiling, rare cell detection, and early disease identification 48 4.2.4 CHALLENGES 49 4.2.4.1 Complexity in managing and interpreting data generated by next-generation hematology analyzers 49 4.2.4.2 Shortage of laboratory workforce 49 4.3 UNMET NEEDS 50 4.4 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 50 5 INDUSTRY TRENDS 52 5.1 PORTER’S FIVE FORCES ANALYSIS 52 5.1.1 INTENSITY OF COMPETITIVE RIVALRY 53 5.1.2 BARGAINING POWER OF BUYERS 53 5.1.3 BARGAINING POWER OF SUPPLIERS 53 5.1.4 THREAT OF NEW ENTRANTS 53 5.1.5 THREAT OF SUBSTITUTES 53 5.2 MACROECONOMIC OUTLOOK 54 5.2.1 INTRODUCTION 54 5.2.2 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 54 5.2.3 MACROECONOMIC OUTLOOK FOR EUROPE 54 5.2.4 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 55 5.2.5 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 55 5.2.6 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 56 5.2.7 TRENDS IN GLOBAL IN-VITRO DIAGNOSTICS (IVD) INDUSTRY 56 5.2.8 TRENDS IN GLOBAL POINT-OF-CARE (POC) DIAGNOSTICS INDUSTRY 56 5.3 VALUE CHAIN ANALYSIS 57 5.4 ECOSYSTEM ANALYSIS 58 5.5 PRICING ANALYSIS 59 5.5.1 PRICING TREND OF HEMATOLOGY INSTRUMENTS, BY REGION, 2023–2025 60 5.5.2 AVERAGE SELLING PRICE OF HEMATOLOGY ANALYZERS AND REAGENTS, BY PRICE RANGE, 2025 62 5.6 TRADE DATA ANALYSIS 63 5.6.1 IMPORT DATA (HS CODE 902780) 63 5.6.2 EXPORT DATA (HS CODE 902780) 64 5.7 KEY CONFERENCES AND EVENTS, 2026–2027 65 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 66 5.9 INVESTMENT AND FUNDING SCENARIO 67   5.10 CASE STUDY ANALYSIS 68 5.10.1 DETECTION OF ABNORMAL WBC POPULATIONS IN HIGH WBC COUNT CASES USING XN-SERIES AUTOMATED HEMATOLOGY ANALYZER 68 5.10.2 MONITORING AND DETECTION OF ACUTE MYELOBLASTIC LEUKEMIA (AML-M1) USING ADVANCED HEMATOLOGY ANALYZERS 69 5.10.3 DETECTION OF MICROCYTIC ANEMIA WITH THROMBOCYTOSIS THROUGH ADVANCED SCATTERGRAM ANALYSIS 69 5.11 IMPACT OF US TARIFFS – HEMATOLOGY ANALYZERS AND REAGENTS MARKET 70 5.11.1 INTRODUCTION 70 5.11.2 KEY TARIFF RATES 70 5.11.3 PRICE IMPACT ANALYSIS 70 5.11.4 IMPACT ON COUNTRIES/REGIONS 71 5.11.4.1 US 71 5.11.4.2 Europe 71 5.11.4.3 Asia Pacific 72 5.11.5 IMPACT ON END USERS 72 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACTS, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 73 6.1 KEY TECHNOLOGIES 73 6.1.1 FLOW CYTOMETRY 73 6.1.2 DIGITAL MORPHOLOGY ANALYZERS 73 6.1.3 MICROFLUIDICS 74 6.2 COMPLEMENTARY TECHNOLOGIES 74 6.2.1 LABORATORY INFORMATION SYSTEMS 74 6.2.2 CLOUD & REMOTE DIAGNOSTICS 74 6.3 PATENT ANALYSIS 75 6.4 FUTURE APPLICATIONS 77 6.5 IMPACT OF AI/GEN AI ON HEMATOLOGY ANALYZERS AND REAGENTS MARKET 77 6.5.1 TOP USE CASES AND MARKET POTENTIAL 78 6.5.2 BEST PRACTICES FOLLOWED BY COMPANIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 79 6.5.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 80 6.5.4 INTERCONNECTED ECOSYSTEM AND IMPACT ON MARKET PLAYERS 80 6.5.5 CLIENTS' READINESS TO ADOPT AI/GEN AI-INTEGRATED HEMATOLOGY ANALYZERS AND REAGENTS 81 6.6 SUCCESS STORIES AND REAL-WORLD APPLICATIONS 81 7 REGULATORY LANDSCAPE 83 7.1 REGIONAL REGULATIONS AND COMPLIANCE 83 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83 7.1.2 REGULATORY TRENDS 86 8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR 90 8.1 DECISION-MAKING PROCESS 90 8.2 KEY STAKEHOLDERS IN BUYING PROCESS AND EVALUATION CRITERIA 91 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 92 8.2.2 BUYING CRITERIA 92 8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES 93 8.4 UNMET NEEDS OF VARIOUS END USERS 94 9 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE 97 9.1 INTRODUCTION 98 9.2 LOW-RANGE HEMATOLOGY ANALYZERS 99 9.2.1 LOW OPERATING EXPENSES TO ACCELERATE SEGMENTAL GROWTH 99 9.3 HIGH-RANGE HEMATOLOGY ANALYZERS 100 9.3.1 HIGH ACCURACY AND MULTI-PARAMETER APPROACH TO FUEL SEGMENTAL GROWTH 100 9.4 MID-RANGE HEMATOLOGY ANALYZERS 101 9.4.1 INTEGRATION WITH QUALITY CONTROL SOFTWARE TO SUPPORT SEGMENTAL GROWTH 101 10 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE 103 10.1 INTRODUCTION 104 10.2 STANDALONE ANALYZERS 104 10.2.1 INCREASING DEMAND FOR HIGH-THROUGHPUT AND AUTOMATED LABORATORY WORKFLOWS TO FOSTER SEGMENTAL GROWTH 104 10.3 POINT-OF-CARE ANALYZERS 105 10.3.1 SHIFTING PREFERENCE TOWARD DECENTRALIZED AND RAPID DIAGNOSTICS TO EXPEDITE SEGMENTAL GROWTH 105 11 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE 107 11.1 INTRODUCTION 108 11.2 HEMATOLOGY PRODUCTS & SERVICES 108 11.2.1 REAGENTS & CONSUMABLES 110 11.2.1.1 Hematology reagents 111 11.2.1.1.1 Growing preference for rental business models to drive market 111 11.2.1.2 Hematology consumables 112 11.2.1.2.1 Requirement for accurate and efficient blood analysis in laboratory workflows to spur demand 112 11.2.1.3 Controls & calibrators 113 11.2.1.3.1 Ability to monitor multiple parameters to boost segmental growth 113   11.2.1.4 Slide stainers & makers 114 11.2.1.4.1 Detailed visualization of cellular morphology to augment segmental growth 114 11.2.2 INSTRUMENTS 115 11.2.2.1 5-part & 6-part fully automated hematology analyzers 117 11.2.2.1.1 Identification and classification of WBCs to drive market 117 11.2.2.2 3-part fully automated hematology analyzers 118 11.2.2.2.1 Low maintenance costs to contribute to segmental growth 118 11.2.2.3 Point-of-care & semi-automated testing hematology analyzers 119 11.2.2.3.1 Shift toward decentralized, rapid, and multi-parameter hematology testing to spur demand 119 11.2.3 SERVICES 120 11.2.3.1 High adoption of diagnostic techniques to boost segmental growth 120 11.3 HEMOSTASIS PRODUCTS & SERVICES 121 11.3.1 HEMOSTASIS REAGENTS & CONSUMABLES 122 11.3.1.1 Expanding use in comprehensive coagulation testing and specialized diagnostics to fuel segmental growth 122 11.3.2 HEMOSTASIS INSTRUMENTS 122 11.3.2.1 High productivity with low complexities to drive market 122 11.3.3 HEMOSTASIS SERVICES 123 11.3.3.1 Advancements in hemostasis diagnostic techniques to support segmental growth 123 11.4 IMMUNOHEMATOLOGY PRODUCTS & SERVICES 124 11.4.1 IMMUNOHEMATOLOGY REAGENTS & CONSUMABLES 125 11.4.1.1 Use to ensure accurate transfusion testing and enhance blood safety to bolster segmental growth 125 11.4.2 IMMUNOHEMATOLOGY INSTRUMENTS 126 11.4.2.1 Growing automation in immunohematology labs to foster segmental growth 126 11.4.3 SERVICES 127 11.4.3.1 Provision of customer-focused care to support segmental growth 127 12 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION 128 12.1 INTRODUCTION 129 12.2 HEMORRHAGIC CONDITIONS 129 12.2.1 INCREASING DEMAND FOR DECENTRALIZED AND FREQUENT MONITORING TO EXPEDITE SEGMENTAL GROWTH 129 12.3 INFECTIOUS DISEASES 130 12.3.1 NEED FOR RAPID SCREENING TO ACCELERATE SEGMENTAL GROWTH 130 12.4 IMMUNE SYSTEM DISORDERS 131 12.4.1 FOCUS ON ADVANCED BLOOD PROFILING TO FACILITATE SEGMENTAL GROWTH 131 12.5 BLOOD CANCER 132 12.5.1 ABILITY TO IDENTIFY ABNORMAL BLOOD CELLS AND MORPHOLOGICAL ABNORMALITIES TO DRIVE MARKET 132 12.6 ANEMIA 134 12.6.1 SHIFT TOWARD ADVANCED RBC PARAMETER ANALYSIS TO BOOST SEGMENTAL GROWTH 134 12.7 OTHER APPLICATIONS 135 13 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER 136 13.1 INTRODUCTION 137 13.2 COMMERCIAL SERVICE PROVIDERS 137 13.2.1 HIGH EMPHASIS ON HIGH-VOLUME ROUTINE TESTING, PREVENTIVE SCREENING, AND ADVANCED DIAGNOSTICS TO DRIVE MARKET 137 13.3 HOSPITAL LABORATORIES 139 13.3.1 RISING NEED FOR REAL-TIME PATIENT DIAGNOSIS AND EMERGENCY TESTING TO EXPEDITE SEGMENTAL GROWTH 139 13.4 GOVERNMENT REFERENCE LABORATORIES 140 13.4.1 INCREASING NEED FOR LARGE-SCALE DISEASE SURVEILLANCE, SCREENING, AND DIAGNOSTIC STANDARDIZATION TO SPUR DEMAND 140 13.5 RESEARCH & ACADEMIC INSTITUTES 141 13.5.1 GROWING FOCUS ON ADVANCED DISEASE PROFILING, BIOMARKER DISCOVERY, AND TRANSLATIONAL RESEARCH TO BOOST SEGMENTAL GROWTH 141 14 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION 142 14.1 INTRODUCTION 143 14.2 NORTH AMERICA 143 14.2.1 US 149 14.2.1.1 Rising incidence of anemia and hemophilia to drive market 149 14.2.2 CANADA 150 14.2.2.1 Mounting demand for accurate blood diagnostics to bolster market growth 150 14.3 EUROPE 151 14.3.1 GERMANY 156 14.3.1.1 Increasing prevalence of anemia to contribute to market growth 156 14.3.2 FRANCE 157 14.3.2.1 Rising adoption of automated and high-throughput hematology analyzers to support market growth 157 14.3.3 UK 158 14.3.3.1 High incidence of blood-related disorders to expedite market growth 158 14.3.4 ITALY 159 14.3.4.1 Growing acceptance of hematology-based diagnostics to boost market growth 159 14.3.5 SPAIN 159 14.3.5.1 Rising preference for automated and high-throughput hematology systems to augment market growth 159 14.3.6 REST OF EUROPE 160   14.4 ASIA PACIFIC 161 14.4.1 CHINA 167 14.4.1.1 Large target patient population to expedite market growth 167 14.4.2 JAPAN 168 14.4.2.1 Rising cases of influenza to support market growth 168 14.4.3 INDIA 169 14.4.3.1 Government-led procurement initiatives and expanding diagnostic infrastructure to fuel market growth 169 14.4.4 AUSTRALIA 170 14.4.4.1 Increasing prevalence of celiac disease to drive market 170 14.4.5 SOUTH KOREA 171 14.4.5.1 Strong focus on advanced diagnostics and automation to contribute to market growth 171 14.4.6 REST OF ASIA PACIFIC 171 14.5 LATIN AMERICA 172 14.5.1 BRAZIL 177 14.5.1.1 Increasing burden of anemia and infectious diseases to expedite market growth 177 14.5.2 MEXICO 178 14.5.2.1 Mounting demand for diagnostic testing to accelerate market growth 178 14.5.3 REST OF LATIN AMERICA 179 14.6 MIDDLE EAST & AFRICA 179 14.6.1 HIGH DISEASE AWARENESS, IMPROVING HEALTHCARE INFRASTRUCTURE, AND ADVANCED TREATMENT OPTIONS TO DRIVE MARKET 179 14.6.2 GCC COUNTRIES 184 14.6.3 REST OF MIDDLE EAST & AFRICA 185 15 COMPETITIVE LANDSCAPE 186 15.1 OVERVIEW 186 15.2 KEY PLAYERS COMPETITIVE STRATEGIES/RIGHT TO WIN, 2022–2026 186 15.3 REVENUE ANALYSIS, 2021–2025 188 15.4 MARKET SHARE ANALYSIS, 2025 189 15.5 MARKET RANKING, 2025 192 15.6 COMPANY VALUATION AND FINANCIAL METRICS 192 15.7 PRODUCT COMPARISON 193 15.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 194 15.8.1 STARS 194 15.8.2 EMERGING LEADERS 194 15.8.3 PERVASIVE PLAYERS 194 15.8.4 PARTICIPANTS 194 15.8.5 COMPETITIVE FOOTPRINT: KEY PLAYERS, 2025 196 15.8.5.1 Company footprint 196 15.8.5.2 Region footprint 197 15.8.5.3 Product & service footprint 198 15.8.5.4 Application footprint 199 15.8.5.5 End user footprint 200 15.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 201 15.9.1 PROGRESSIVE COMPANIES 201 15.9.2 RESPONSIVE COMPANIES 201 15.9.3 DYNAMIC COMPANIES 201 15.9.4 STARTING BLOCKS 201 15.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 203 15.9.5.1 Detailed list of key startups/SMEs 203 15.9.5.2 Competitive benchmarking of key startups/SMEs 204 15.10 COMPETITIVE SCENARIO 205 15.10.1 PRODUCT LAUNCHES AND APPROVALS 205 15.10.2 DEALS 206 15.10.3 EXPANSIONS 206 16 COMPANY PROFILES 208 16.1 KEY PLAYERS 208 16.1.1 SYSMEX CORPORATION 208 16.1.1.1 Business overview 208 16.1.1.2 Products offered 209 16.1.1.3 Recent developments 211 16.1.1.3.1 Deals 211 16.1.1.3.2 Expansions 212 16.1.1.4 MnM view 213 16.1.1.4.1 Right to win 213 16.1.1.4.2 Strategic choices 213 16.1.1.4.3 Weaknesses and competitive threats 213 16.1.2 ABBOTT 214 16.1.2.1 Business overview 214 16.1.2.2 Products offered 215 16.1.2.3 Recent developments 216 16.1.2.3.1 Product launches and approvals 216 16.1.2.4 MnM view 217 16.1.2.4.1 Right to win 217 16.1.2.4.2 Strategic choices 217 16.1.2.4.3 Weaknesses and competitive threats 217   16.1.3 DANAHER CORPORATION 218 16.1.3.1 Business overview 218 16.1.3.2 Products offered 219 16.1.3.3 Recent developments 220 16.1.3.3.1 Deals 220 16.1.3.4 MnM view 220 16.1.3.4.1 Right to win 220 16.1.3.4.2 Strategic choices 221 16.1.3.4.3 Weaknesses and competitive threats 221 16.1.4 SIEMENS HEALTHINEERS AG 222 16.1.4.1 Business overview 222 16.1.4.2 Products offered 223 16.1.4.3 Recent developments 225 16.1.4.3.1 Product launches and approvals 225 16.1.4.3.2 Deals 225 16.1.4.4 MnM view 225 16.1.4.4.1 Right to win 225 16.1.4.4.2 Strategic choices 225 16.1.4.4.3 Weaknesses and competitive threats 226 16.1.5 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 227 16.1.5.1 Business overview 227 16.1.5.2 Products offered 228 16.1.5.3 Recent developments 229 16.1.5.3.1 Product launches and approvals 229 16.1.5.4 MnM view 229 16.1.5.4.1 Right to win 229 16.1.5.4.2 Strategic choices 229 16.1.5.4.3 Weaknesses and competitive threats 229 16.1.6 DIATRON 230 16.1.6.1 Business overview 230 16.1.6.2 Products offered 230 16.1.6.3 Recent developments 231 16.1.6.3.1 Expansions 231 16.1.7 DREW SCIENTIFIC 232 16.1.7.1 Business overview 232 16.1.7.2 Products offered 232 16.1.8 BIO-RAD LABORATORIES, INC. 233 16.1.8.1 Business overview 233 16.1.8.2 Products offered 234 16.1.8.3 Recent developments 235 16.1.8.3.1 Product launches and approvals 235   16.1.9 HORIBA 236 16.1.9.1 Business overview 236 16.1.9.2 Products offered 237 16.1.9.3 Recent developments 239 16.1.9.3.1 Product launches and approvals 239 16.1.10 NIHON KOHDEN CORPORATION 240 16.1.10.1 Business overview 240 16.1.10.2 Products offered 241 16.1.10.3 Recent developments 242 16.1.10.3.1 Expansions 242 16.1.11 EKF DIAGNOSTICS HOLDINGS PLC 243 16.1.11.1 Business overview 243 16.1.11.2 Products offered 244 16.1.11.3 Recent developments 245 16.1.11.3.1 Product launches and approvals 245 16.1.12 BOULE 246 16.1.12.1 Business overview 246 16.1.12.2 Products offered 247 16.1.12.3 Recent developments 248 16.1.12.3.1 Product launches and approvals 248 16.1.12.3.2 Deals 248 16.1.13 F. HOFFMANN-LA ROCHE LTD 249 16.1.13.1 Business overview 249 16.1.13.2 Products offered 250 16.1.13.3 Recent developments 251 16.1.13.3.1 Deals 251 16.1.14 BIOSYSTEMS DIAGNOSTICS 252 16.1.14.1 Business overview 252 16.1.14.2 Products offered 252 16.2 OTHER PLAYERS 253 16.2.1 DRUCKER DIAGNOSTICS 253 16.2.2 ACCUREX 254 16.2.3 STRECK 255 16.2.4 NEOMEDICA 256 16.2.5 EVERLIFE CPC 257 16.2.6 MERIL 258 16.2.7 SHENZHEN DYMIND BIOTECHNOLOGY CO., LTD. 259 16.2.8 PZ CORMAY S.A. 260 16.2.9 PIXCELL MEDICAL 262 16.2.10 RAYTO LIFE AND ANALYTICAL SCIENCES CO.,LTD. 263 16.2.11 ANALYTICON BIOTECHNOLOGIES GMBH 264 17 RESEARCH METHODOLOGY 265 17.1 INTRODUCTION 265 17.2 RESEARCH DATA 266 17.2.1 SECONDARY DATA 266 17.2.1.1 List of key secondary sources 267 17.2.1.2 Key data from secondary sources 268 17.2.2 PRIMARY RESEARCH 268 17.2.2.1 Key data from primary sources 269 17.2.2.2 Primary research objectives 269 17.2.2.3 Key industry insights 270 17.2.2.4 Breakdown of primaries 271 17.2.2.5 List of primary interview participants 271 17.3 MARKET SIZE ESTIMATION 272 17.3.1 BOTTOM-UP APPROACH 274 17.3.2 TOP-DOWN APPROACH 275 17.4 GROWTH FORECAST 276 17.5 DATA TRIANGULATION 278 17.6 MARKET SHARE ASSESSMENT 278 17.7 RESEARCH ASSUMPTIONS 279 17.8 RESEARCH LIMITATIONS 279 17.9 RISK ANALYSIS 280 18 APPENDIX 281 18.1 DISCUSSION GUIDE 281 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 288 18.3 CUSTOMIZATION OPTIONS 290 18.4 RELATED REPORTS 290 18.5 AUTHOR DETAILS 291
圖表清單 List of Tables & Figures
TABLE 1 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: INCLUSIONS AND EXCLUSIONS 28 TABLE 2 IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 44 TABLE 3 POTENTIAL BIOMARKERS DETECTABLE BY NEXT-GENERATION HEMATOLOGY ANALYZERS 48 TABLE 4 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: UNMET NEEDS 50 TABLE 5 STRATEGIC FOCUS OF TIER-1/2/3 PLAYERS 51 TABLE 6 IMPACT OF PORTER’S FIVE FORCES ANALYSIS 52 TABLE 7 NORTH AMERICA: MACROECONOMIC OUTLOOK 54 TABLE 8 EUROPE: MACROECONOMIC OUTLOOK 55 TABLE 9 ASIA PACIFIC: MACROECONOMIC OUTLOOK 55 TABLE 10 LATIN AMERICA: MACROECONOMIC OUTLOOK 56 TABLE 11 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 56 TABLE 12 ROLE OF COMPANIES IN HEMATOLOGY ANALYZERS AND REAGENTS ECOSYSTEM 59 TABLE 13 PRICING TREND OF HEMATOLOGY INSTRUMENTS, BY REGION, 2023–2025 (USD THOUSAND) 61 TABLE 14 AVERAGE SELLING PRICE OF HEMATOLOGY ANALYZERS AND REAGENTS, BY PRICE RANGE, 2025 (USD THOUSAND) 62 TABLE 15 AVERAGE SELLING PRICE OF HEMATOLOGY REAGENTS & CONSUMABLES, BY KEY PLAYER, 2025 (USD THOUSAND) 63 TABLE 16 IMPORT DATA FOR HS CODE 902780-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 63 TABLE 17 EXPORT DATA FOR HS CODE 902780-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 64 TABLE 18 LIST OF KEY CONFERENCES AND EVENTS, 2026–2027 65 TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES IN MEDTECH INDUSTRY 70 TABLE 20 TARIFF-INDUCED PRICE INCREASES FOR HEALTHCARE PRODUCTS 71 TABLE 21 INNOVATIONS AND PATENT REGISTRATIONS, 2020–2024 76 TABLE 22 KEY COMPANIES IMPLEMENTING AI/GEN AI IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 80 TABLE 23 KEY APPLICATIONS AND CLINICAL OUTCOMES ENABLED BY HEMATOLOGY ANALYZERS 82 TABLE 24 NORTH AMERICA: LIST OF REGULATORY AUTHORITIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 83 TABLE 25 EUROPE: LIST OF REGULATORY AUTHORITIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 84 TABLE 26 ASIA PACIFIC: LIST OF REGULATORY AUTHORITIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 84 TABLE 27 LATIN AMERICA: LIST OF REGULATORY AUTHORITIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 85 TABLE 28 MIDDLE EAST & AFRICA: LIST OF REGULATORY AUTHORITIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 85 TABLE 29 IMPACT OF CLIA 2024 ON HEMATOLOGY ANALYZERS AND REAGENTS MARKET 87 TABLE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%) 92 TABLE 31 BUYING CRITERIA, BY PRODUCT & SERVICE 93 TABLE 32 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: UNMET NEED ANALYSIS, BY END USER 95 TABLE 33 HEMATOLOGY ANALYZER SEGMENTATION, BY SYSTEM TYPE, PERFORMANCE, AND PRICING 98 TABLE 34 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE, 2024–2031 (USD MILLION) 98 TABLE 35 LOW-RANGE HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 99 TABLE 36 HIGH-RANGE HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 101 TABLE 37 MID-RANGE HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 102 TABLE 38 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE, 2024–2031 (USD MILLION) 104 TABLE 39 STANDALONE ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 105 TABLE 40 POINT-OF-CARE ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 106 TABLE 41 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 108 TABLE 42 HEMATOLOGY PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 109 TABLE 43 HEMATOLOGY PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 110 TABLE 44 HEMATOLOGY REAGENTS & CONSUMABLES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 110 TABLE 45 HEMATOLOGY REAGENTS & CONSUMABLES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 111 TABLE 46 HEMATOLOGY REAGENTS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 112 TABLE 47 HEMATOLOGY CONSUMABLES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 113 TABLE 48 HEMATOLOGY CONTROLS & CALIBRATORS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 114 TABLE 49 HEMATOLOGY SLIDE STAINERS & MAKERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 115 TABLE 50 HEMATOLOGY INSTRUMENTS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 116 TABLE 51 HEMATOLOGY INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 116 TABLE 52 5-PART VS. 6-PART FULLY AUTOMATED HEMATOLOGY ANALYZERS 117 TABLE 53 5-PART & 6-PART FULLY AUTOMATED HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 118 TABLE 54 3-PART FULLY AUTOMATED HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 119 TABLE 55 POINT-OF-CARE & SEMI-AUTOMATED TESTING HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 120 TABLE 56 HEMATOLOGY SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 120 TABLE 57 HEMOSTASIS PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 121 TABLE 58 HEMOSTASIS PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 121 TABLE 59 HEMOSTASIS REAGENTS & CONSUMABLES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 122 TABLE 60 HEMOSTASIS INSTRUMENTS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 123 TABLE 61 HEMOSTASIS SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 124 TABLE 62 IMMUNOHEMATOLOGY PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 124 TABLE 63 IMMUNOHEMATOLOGY PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 125 TABLE 64 IMMUNOHEMATOLOGY REAGENTS & CONSUMABLES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 126 TABLE 65 IMMUNOHEMATOLOGY INSTRUMENTS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 127 TABLE 66 IMMUNOHEMATOLOGY SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 127 TABLE 67 HAEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 129 TABLE 68 HEMORRHAGIC CONDITIONS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 130 TABLE 69 INFECTIOUS DISEASES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 131 TABLE 70 IMMUNE SYSTEM DISORDERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 132 TABLE 71 BLOOD CANCER: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 133 TABLE 72 ANEMIA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 134 TABLE 73 OTHER APPLICATIONS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 135 TABLE 74 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER, 2024–2031 (USD MILLION) 137 TABLE 75 COMMERCIAL SERVICE PROVIDERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 138 TABLE 76 HOSPITAL LABORATORIES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 139 TABLE 77 GOVERNMENT REFERENCE LABORATORIES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 140 TABLE 78 RESEARCH & ACADEMIC INSTITUTES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 141 TABLE 79 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 143 TABLE 80 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144 TABLE 81 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 145 TABLE 82 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 145 TABLE 83 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 146 TABLE 84 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMOSTASIS PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 146 TABLE 85 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR IMMUNOHEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 147 TABLE 86 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE, 2024–2031 (USD MILLION) 147 TABLE 87 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 148 TABLE 88 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE, 2024–2031 (USD MILLION) 148 TABLE 89 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER, 2024–2031 (USD MILLION) 149 TABLE 90 US: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 150 TABLE 91 CANADA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 151 TABLE 92 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152 TABLE 93 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 152 TABLE 94 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 153 TABLE 95 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 153 TABLE 96 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMOSTASIS PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 154 TABLE 97 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR IMMUNOHEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 154 TABLE 98 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE, 2024–2031 (USD MILLION) 154 TABLE 99 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 155 TABLE 100 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE, 2024–2031 (USD MILLION) 155 TABLE 101 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER, 2024–2031 (USD MILLION) 155 TABLE 102 GERMANY: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 156 TABLE 103 FRANCE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 157 TABLE 104 UK: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 158 TABLE 105 ITALY: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 159 TABLE 106 SPAIN: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 160 TABLE 107 REST OF EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 161 TABLE 108 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 162 TABLE 109 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 163 TABLE 110 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 163 TABLE 111 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 164 TABLE 112 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMOSTASIS PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 164 TABLE 113 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR IMMUNOHEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 165 TABLE 114 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE, 2024–2031 (USD MILLION) 165 TABLE 115 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 166 TABLE 116 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE, 2024–2031 (USD MILLION) 166 TABLE 117 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER, 2024–2031 (USD MILLION) 166 TABLE 118 CHINA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 167 TABLE 119 JAPAN: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 168 TABLE 120 INDIA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 169 TABLE 121 AUSTRALIA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 170 TABLE 122 SOUTH KOREA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 171 TABLE 123 REST OF ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 172 TABLE 124 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 172 TABLE 125 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 173 TABLE 126 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 173 TABLE 127 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 174 TABLE 128 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMOSTASIS PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 174 TABLE 129 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR IMMUNOHEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 175 TABLE 130 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY ANALYZERS AND REAGENTS, BY PRICE RANGE, 2024–2031 (USD MILLION) 175 TABLE 131 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY ANALYZERS AND REAGENTS, BY APPLICATION, 2024–2031 (USD MILLION) 176 TABLE 132 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY ANALYZERS AND REAGENTS, BY USAGE TYPE, 2024–2031 (USD MILLION) 176 TABLE 133 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY ANALYZERS AND REAGENTS, BY END USER, 2024–2031 (USD MILLION) 177 TABLE 134 BRAZIL: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 178 TABLE 135 MEXICO: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 178 TABLE 136 REST OF LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 179 TABLE 137 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 138 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 180 TABLE 139 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 180 TABLE 140 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 181 TABLE 141 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMOSTASIS PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 181 TABLE 142 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR IMMUNOHEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 182 TABLE 143 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE, 2024–2031 (USD MILLION) 182 TABLE 144 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 183 TABLE 145 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE, 2024–2031 (USD MILLION) 183 TABLE 146 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER, 2024–2031 (USD MILLION) 184 TABLE 147 GCC COUNTRIES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 184 TABLE 148 REST OF MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 185 TABLE 149 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, JANUARY 2022–MARCH 2026 187 TABLE 150 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: DEGREE OF COMPETITION, 2025 189 TABLE 151 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: REGION FOOTPRINT 197 TABLE 152 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: PRODUCT & SERVICE FOOTPRINT 198 TABLE 153 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: APPLICATION FOOTPRINT 199 TABLE 154 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: END USER FOOTPRINT 200 TABLE 155 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 203 TABLE 156 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 204 TABLE 157 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2026 205 TABLE 158 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: DEALS, JANUARY 2022–MARCH 2026 206 TABLE 159 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: EXPANSIONS, JANUARY 2022–MARCH 2026 206 TABLE 160 SYSMEX CORPORATION: COMPANY OVERVIEW 208 TABLE 161 SYSMEX CORPORATION: PRODUCTS OFFERED 209 TABLE 162 SYSMEX CORPORATION: DEALS, JANUARY 2022–MARCH 2026 211 TABLE 163 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2022–MARCH 2026 212 TABLE 164 ABBOTT: COMPANY OVERVIEW 214 TABLE 165 ABBOTT: PRODUCTS OFFERED 215 TABLE 166 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2026 216 TABLE 167 DANAHER CORPORATION: COMPANY OVERVIEW 218 TABLE 168 DANAHER CORPORATION: PRODUCTS OFFERED 219 TABLE 169 DANAHER CORPORATION: DEALS, JANUARY 2022–NOVEMBER 2025 220 TABLE 170 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 222 TABLE 171 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 223 TABLE 172 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022– MARCH 2026 225 TABLE 173 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022– MARCH 2026 225 TABLE 174 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW 227 TABLE 175 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED 228 TABLE 176 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025 229 TABLE 177 DIATRON: COMPANY OVERVIEW 230 TABLE 178 DIATRON: PRODUCTS OFFERED 230 TABLE 179 DIATRON: EXPANSIONS, JANUARY 2022–MARCH 2026 231 TABLE 180 DREW SCIENTIFIC: COMPANY OVERVIEW 232 TABLE 181 DREW SCIENTIFIC: PRODUCTS OFFERED 232 TABLE 182 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 233 TABLE 183 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 234 TABLE 184 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2026 235 TABLE 185 HORIBA: COMPANY OVERVIEW 236 TABLE 186 HORIBA: PRODUCTS OFFERED 237 TABLE 187 HORIBA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2026 239 TABLE 188 NIHON KOHDEN CORPORATION: COMPANY OVERVIEW 240 TABLE 189 NIHON KOHDEN CORPORATION: PRODUCTS OFFERED 241 TABLE 190 NIHON KOHDEN CORPORATION: DEALS, JANUARY 2022–MARCH 2026 242 TABLE 191 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW 243 TABLE 192 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCTS OFFERED 244 TABLE 193 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2026 245 TABLE 194 BOULE: COMPANY OVERVIEW 246 TABLE 195 BOULE: PRODUCTS OFFERED 247 TABLE 196 BOULE: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2026 248 TABLE 197 BOULE: DEALS, JANUARY 2022–MARCH 2026 248 TABLE 198 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 249 TABLE 199 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 250 TABLE 200 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2022–MARCH 2025 251 TABLE 201 BIOSYSTEMS DIAGNOSTICS: COMPANY OVERVIEW 252 TABLE 202 BIOSYSTEMS DIAGNOSTICS: PRODUCTS OFFERED 252 TABLE 203 DRUCKER DIAGNOSTICS: COMPANY OVERVIEW 253 TABLE 204 ACCUREX: COMPANY OVERVIEW 254 TABLE 205 STRECK: COMPANY OVERVIEW 255 TABLE 206 NEOMEDICA: COMPANY OVERVIEW 256 TABLE 207 EVERLIFE CPC: COMPANY OVERVIEW 257 TABLE 208 MERIL: COMPANY OVERVIEW 258 TABLE 209 SHENZHEN DYMIND BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW 259 TABLE 210 PZ CORMAY S.A.: COMPANY OVERVIEW 260 TABLE 211 PIXCELL MEDICAL: COMPANY OVERVIEW 262 TABLE 212 RAYTO LIFE AND ANALYTICAL SCIENCES CO.,LTD.: COMPANY OVERVIEW 263 TABLE 213 ANALYTICON BIOTECHNOLOGIES GMBH: COMPANY OVERVIEW 264 TABLE 214 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: RESEARCH ASSUMPTIONS 279 TABLE 215 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: RISK ANALYSIS 280 FIGURE 1 HEMATOLOGY ANALYZERS AND REAGENTS MARKET SEGMENTATION AND REGIONAL SCOPE 27 FIGURE 2 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: DURATION CONSIDERED 30 FIGURE 3 HEMATOLOGY ANALYZERS AND REAGENTS MARKET SCENARIO 34 FIGURE 4 GLOBAL HEMATOLOGY ANALYZERS AND REAGENTS MARKET SIZE, 2024–2031 34 FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET, 2022–2026 35 FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF HEMATOLOGY ANALYZERS AND REAGENTS MARKET 36 FIGURE 7 HIGH-GROWTH SEGMENTS IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET, 2026–2031 37 FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET DURING FORECAST PERIOD 38 FIGURE 9 INCREASING HEALTHCARE INVESTMENTS AND AWARENESS ABOUT EARLY DISEASE DIAGNOSIS TO DRIVE HEMATOLOGY ANALYZERS AND REAGENTS MARKET 39 FIGURE 10 NORTH AMERICA TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD 40 FIGURE 11 COMMERCIAL SERVICE PROVIDERS AND CHINA ACCOUNTED FOR LARGEST MARKET SHARE IN ASIA PACIFIC IN 2025 41 FIGURE 12 CHINA TO REGISTER HIGHEST GROWTH RATE FROM 2026 TO 2031 42 FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 43 FIGURE 14 PORTER’S FIVE FORCES ANALYSIS 52 FIGURE 15 HEMATOLOGY ANALYZERS AND REAGENTS VALUE CHAIN ANALYSIS 57 FIGURE 16 HEMATOLOGY ANALYZERS AND REAGENTS ECOSYSTEM ANALYSIS 58 FIGURE 17 PRICING TREND OF HEMATOLOGY INSTRUMENTS, BY REGION, 2023–2025 61 FIGURE 18 AVERAGE SELLING PRICE OF HEMATOLOGY ANALYZERS AND REAGENTS, BY PRICE RANGE, 2025 62 FIGURE 19 IMPORT DATA FOR HS CODE 902780-COMPLIANT PRODUCTS FOR TOP FIVE COUNTRIES, 2021–2025 64 FIGURE 20 EXPORT DATA FOR HS CODE 902780-COMPLIANT PRODUCTS FOR TOP FIVE COUNTRIES, 2021–2025 65 FIGURE 21 TRENDS/DISRUPTIONS INFLUENCING CUSTOMER BUSINESS 66 FIGURE 22 INVESTMENT AND FUNDING SCENARIO, 2019–2023 67 FIGURE 23 NUMBER OF DEALS, BY KEY PLAYER, 2019–2023 67 FIGURE 24 DEAL VALUES, BY KEY PLAYER, 2019–2023 68 FIGURE 25 PATENTS APPLIED AND GRANTED, 2016–2025 75 FIGURE 26 KEY AI/GEN AI USE CASES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 79 FIGURE 27 HEMATOLOGY ANALYZER AND REAGENTS MARKET: DECISION-MAKING FACTORS 91 FIGURE 28 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE 92 FIGURE 29 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 93 FIGURE 30 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: UNMET NEED ANALYSIS 96 FIGURE 31 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET SNAPSHOT 144 FIGURE 32 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET SNAPSHOT 162 FIGURE 33 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: REVENUE ANALYSIS OF TOP FOUR PLAYERS, 2021−2025 188 FIGURE 34 MARKET SHARE ANALYSIS OF COMPANIES OFFERING HEMATOLOGY ANALYZERS AND REAGENTS, 2025 189 FIGURE 35 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: RANKING OF KEY PLAYERS, 2025 192 FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 192 FIGURE 37 FINANCIAL METRICS (EV/EBITDA) 193 FIGURE 38 PRODUCT COMPARATIVE ANALYSIS 193 FIGURE 39 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 195 FIGURE 40 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: COMPANY FOOTPRINT 196 FIGURE 41 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 202 FIGURE 42 SYSMEX CORPORATION: COMPANY SNAPSHOT (2024) 209 FIGURE 43 ABBOTT: COMPANY SNAPSHOT (2025) 215 FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT (2024) 219 FIGURE 45 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024) 223 FIGURE 46 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2025) 227 FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 234 FIGURE 48 HORIBA: COMPANY SNAPSHOT (2025) 237 FIGURE 49 NIHON KOHDEN CORPORATION: COMPANY SNAPSHOT (2025) 241 FIGURE 50 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2024) 244 FIGURE 51 BOULE: COMPANY SNAPSHOT (2024) 247 FIGURE 52 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025) 250 FIGURE 53 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: RESEARCH DATA 265 FIGURE 54 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: RESEARCH DESIGN 266 FIGURE 55 DATA CAPTURED FROM SECONDARY SOURCES 268 FIGURE 56 PRIMARY SOURCES 269 FIGURE 57 CORE FINDINGS FROM INDUSTRY EXPERTS 270 FIGURE 58 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 271 FIGURE 59 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 271 FIGURE 60 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 273 FIGURE 61 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: BOTTOM-UP APPROACH 274 FIGURE 62 HEMATOLOGY ANALYZERS AND REAGENTS MARKET SIZE ESTIMATION (APPROACH 1) 275 FIGURE 63 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: TOP-DOWN APPROACH 276 FIGURE 64 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: MARKET SIZE ESTIMATION 277 FIGURE 65 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: DATA TRIANGULATION 278

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們